1. Home
  2. ACIU vs CMPS Comparison

ACIU vs CMPS Comparison

Compare ACIU & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACIU
  • CMPS
  • Stock Information
  • Founded
  • ACIU 2003
  • CMPS 2020
  • Country
  • ACIU Switzerland
  • CMPS United Kingdom
  • Employees
  • ACIU N/A
  • CMPS N/A
  • Industry
  • ACIU Biotechnology: Pharmaceutical Preparations
  • CMPS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACIU Health Care
  • CMPS Health Care
  • Exchange
  • ACIU Nasdaq
  • CMPS Nasdaq
  • Market Cap
  • ACIU 332.4M
  • CMPS 301.7M
  • IPO Year
  • ACIU 2016
  • CMPS 2020
  • Fundamental
  • Price
  • ACIU $3.40
  • CMPS $4.60
  • Analyst Decision
  • ACIU Strong Buy
  • CMPS Strong Buy
  • Analyst Count
  • ACIU 2
  • CMPS 7
  • Target Price
  • ACIU $12.00
  • CMPS $30.67
  • AVG Volume (30 Days)
  • ACIU 134.3K
  • CMPS 1.2M
  • Earning Date
  • ACIU 11-05-2024
  • CMPS 10-31-2024
  • Dividend Yield
  • ACIU N/A
  • CMPS N/A
  • EPS Growth
  • ACIU N/A
  • CMPS N/A
  • EPS
  • ACIU N/A
  • CMPS N/A
  • Revenue
  • ACIU $48,505,404.00
  • CMPS N/A
  • Revenue This Year
  • ACIU N/A
  • CMPS N/A
  • Revenue Next Year
  • ACIU $938.44
  • CMPS N/A
  • P/E Ratio
  • ACIU N/A
  • CMPS N/A
  • Revenue Growth
  • ACIU 4097200.00
  • CMPS N/A
  • 52 Week Low
  • ACIU $2.25
  • CMPS $4.05
  • 52 Week High
  • ACIU $5.14
  • CMPS $12.75
  • Technical
  • Relative Strength Index (RSI)
  • ACIU 56.02
  • CMPS 37.74
  • Support Level
  • ACIU $3.29
  • CMPS $4.34
  • Resistance Level
  • ACIU $3.48
  • CMPS $4.68
  • Average True Range (ATR)
  • ACIU 0.21
  • CMPS 0.35
  • MACD
  • ACIU 0.03
  • CMPS 0.02
  • Stochastic Oscillator
  • ACIU 45.45
  • CMPS 15.00

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Share on Social Networks: